RASAZILECT rasagiline mesilate1 mg tablets, bottle

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

rasagiline mesilate, Quantity: 1.56 mg

Disponível em:

Arrotex Pharmaceuticals Pty Ltd

Forma farmacêutica:

Tablet, uncoated

Composição:

Excipient Ingredients: purified talc; microcrystalline cellulose; citric acid; silicon dioxide; pregelatinised maize starch; stearic acid; maize starch

Via de administração:

Oral

Unidades em pacote:

30

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Resumo do produto:

Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status de autorização:

Registered

Data de autorização:

2018-01-23